Medical Cannabis and Parkinson's Disease: The Pioneering Trial at La Timone in Marseille
💡 Update note: What is the current status of medical cannabis in France?
This article outlines the history of the first clinical trials conducted at La Timone Hospital in Marseille. To consult the complete and up-to-date status of regulations, the assessment of indications, and the steps for general rollout, discover our updated dossier: Medical Cannabis in France: Experimentation, ANSM and Status.
La Timone Hospital (AP-HM) in Marseille marked a milestone in French medical research by initiating a clinical trial on the use of therapeutic cannabinoids in patients with Parkinson's disease. Led under the direction of Professor Olivier Blin, head of the clinical pharmacology department and director of the Dhune institute, this study was one of the first French initiatives aimed at scientifically evaluating the impact of medical cannabis on this neurodegenerative condition.
1. Origin and Objectives of the Marseille Study
Conceived in consultation with the France Parkinson Association and the Assistance Publique-Hôpitaux de Marseille, this project stemmed from the observation of informal use among certain patients seeking to alleviate their symptoms. The medical team's objective was to regulate these practices through a rigorous scientific approach in order to precisely measure real benefits and potential risks.
The trial involved about thirty participants, including patients suffering from Parkinson's disease at various stages as well as control subjects. This initiative was part of the recommendations of the French National Agency for the Safety of Medicines and Health Products (ANSM), which was preparing the national experiment on cannabis for medical use.
2. Medical Protocol and Symptoms Evaluated
The research focused on the analysis of specific combinations of tetrahydrocannabinol (THC) and cannabidiol (CBD). Administered via nebulization in a single dose, the treatment aimed to observe the body's response across two main areas:
- Motor symptoms: evaluation of the impact on muscle stiffness, general motor skills, and resting tremors.
- Non-motor manifestations: study of the effects on anxiety, depressive mood, behavior, and chronic fatigue, which are major factors in the deterioration of patients' quality of life.
3. Medical Cannabis vs. Wellness CBD: An Essential Distinction
It is crucial not to confuse clinical trials on medical cannabis with the use of over-the-counter CBD products:
- Medical Cannabis: it concerns pharmaceutical specialties containing THC and CBD administered under strict hospital supervision. These products are reserved for evaluation protocols or supervised prescriptions. To understand the biology of these molecules, you can discover how the endocannabinoid system works.
- Wellness CBD: these are legal hemp extracts with a THC content strictly below 0.3%. As they are not medicines, they are used daily to promote a climate of relaxation. To ensure safe consumption, it is advisable to avoid synthetic molecules.
To better grasp the synergy of plant compounds, feel free to understand how the entourage effect works. If you wish to explore natural and raw extracts, you can discover our organic CBD flowers or explore our French CBD resins.
Reminder: wellness CBD is not a medicine and should never replace a prescribed medical treatment.
